WO2022108306A1 - 인터류킨-33을 처리하여 면역원성이 향상된 cd103+ fcgr3+ 수지상세포의 제조방법 및 상기 수지상세포를 포함하는 면역항암치료용 약학적 조성물 - Google Patents
인터류킨-33을 처리하여 면역원성이 향상된 cd103+ fcgr3+ 수지상세포의 제조방법 및 상기 수지상세포를 포함하는 면역항암치료용 약학적 조성물 Download PDFInfo
- Publication number
- WO2022108306A1 WO2022108306A1 PCT/KR2021/016813 KR2021016813W WO2022108306A1 WO 2022108306 A1 WO2022108306 A1 WO 2022108306A1 KR 2021016813 W KR2021016813 W KR 2021016813W WO 2022108306 A1 WO2022108306 A1 WO 2022108306A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dendritic cells
- positive
- present
- cells
- producing
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title claims abstract description 146
- 102000017761 Interleukin-33 Human genes 0.000 title claims abstract description 72
- 108010067003 Interleukin-33 Proteins 0.000 title claims abstract description 72
- 238000000034 method Methods 0.000 title claims abstract description 54
- 230000005847 immunogenicity Effects 0.000 title claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- 238000002619 cancer immunotherapy Methods 0.000 title abstract 2
- 210000001592 cd103-positive dendritic cell Anatomy 0.000 claims abstract description 66
- 239000000427 antigen Substances 0.000 claims abstract description 39
- 108091007433 antigens Proteins 0.000 claims abstract description 39
- 102000036639 antigens Human genes 0.000 claims abstract description 39
- 230000004069 differentiation Effects 0.000 claims abstract description 31
- 108700014844 flt3 ligand Proteins 0.000 claims abstract description 30
- 230000001965 increasing effect Effects 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 17
- 230000001939 inductive effect Effects 0.000 claims abstract description 10
- 210000000130 stem cell Anatomy 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 238000004519 manufacturing process Methods 0.000 claims description 34
- 230000014509 gene expression Effects 0.000 claims description 28
- 238000009169 immunotherapy Methods 0.000 claims description 27
- 101150048700 Fcgr3 gene Proteins 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 claims description 10
- 102100032999 Integrin beta-3 Human genes 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 9
- 108010074328 Interferon-gamma Proteins 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 108010087819 Fc receptors Proteins 0.000 claims description 7
- 102000009109 Fc receptors Human genes 0.000 claims description 7
- 102100037850 Interferon gamma Human genes 0.000 claims description 7
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 6
- 101100369641 Mus musculus Tigit gene Proteins 0.000 claims description 5
- 108010020950 Integrin beta3 Proteins 0.000 claims description 4
- 102000008607 Integrin beta3 Human genes 0.000 claims description 4
- 101710090983 T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 3
- 229940079322 interferon Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 230000005809 anti-tumor immunity Effects 0.000 abstract description 18
- 238000002360 preparation method Methods 0.000 abstract description 12
- 238000002659 cell therapy Methods 0.000 abstract description 9
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract description 7
- 210000002865 immune cell Anatomy 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 229940124597 therapeutic agent Drugs 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 24
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 21
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 230000000694 effects Effects 0.000 description 16
- 102000004127 Cytokines Human genes 0.000 description 15
- 108090000695 Cytokines Proteins 0.000 description 15
- 229940029030 dendritic cell vaccine Drugs 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- 238000010586 diagram Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 8
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- -1 CD86 Proteins 0.000 description 6
- 102000043131 MHC class II family Human genes 0.000 description 6
- 108091054438 MHC class II family Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 101150094945 FCGR3A gene Proteins 0.000 description 5
- 101100334518 Mus musculus Fcgr4 gene Proteins 0.000 description 5
- 230000024245 cell differentiation Effects 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000002100 tumorsuppressive effect Effects 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000024121 nodulation Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000005760 tumorsuppression Effects 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102100035294 Chemokine XC receptor 1 Human genes 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 2
- 101000804783 Homo sapiens Chemokine XC receptor 1 Proteins 0.000 description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 102000054766 genetic haplotypes Human genes 0.000 description 2
- 229940126546 immune checkpoint molecule Drugs 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000015927 pasta Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000037455 tumor specific immune response Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 101100462438 Mus musculus Otulin gene Proteins 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- PMDCZENCAXMSOU-UHFFFAOYSA-N N-ethylacetamide Chemical compound CCNC(C)=O PMDCZENCAXMSOU-UHFFFAOYSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229940045942 acetone sodium bisulfite Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000011130 autologous cell therapy Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- OIJMIQIDIZASII-UHFFFAOYSA-N benzene;benzoic acid Chemical compound C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 OIJMIQIDIZASII-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- IHYNKGRWCDKNEG-UHFFFAOYSA-N n-(4-bromophenyl)-2,6-dihydroxybenzamide Chemical compound OC1=CC=CC(O)=C1C(=O)NC1=CC=C(Br)C=C1 IHYNKGRWCDKNEG-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- YNJORDSKPXMABC-UHFFFAOYSA-M sodium;2-hydroxypropane-2-sulfonate Chemical compound [Na+].CC(C)(O)S([O-])(=O)=O YNJORDSKPXMABC-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2333—Interleukin-33 (IL-33)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
Definitions
- the present invention relates to a method for increasing anti-tumor immunity of dendritic cell therapeutics. Specifically, in the differentiation of dendritic cells into dendritic cells by culturing them in a medium containing Flt3L (FMS-like tyrosine kinase 3 ligand), interleukin-33 (Interleukin-33, IL-) 33), a method for producing a cluster of differentiation 103 (CD103)-positive dendritic cells comprising the step of treating the CD103-positive dendritic cells prepared by the method, and a pharmaceutical composition and kit for immunotherapy comprising the same.
- Flt3L Flt3L
- Interleukin-33 Interleukin-33, IL- 33
- Dendritic cells are representative antigen-presenting cells that can activate cytotoxic T cells by presenting antigens to cytotoxic T cells.
- in vitro cultured dendritic cells are used for tumor treatment.
- Most of the existing in vitro cultured dendritic cells have been using GM-CSF (Granulocyte-macrophage colony-stimulating factor), and recently Flt3L (FMS-like tyrosine kinase 3 ligand) has been used to produce cells more similar to dendritic cells in the body. making it.
- GM-CSF Gramulocyte-macrophage colony-stimulating factor
- Flt3L Flt3L (FMS-like tyrosine kinase 3 ligand) has been used to produce cells more similar to dendritic cells in the body. making it.
- GM/FL-BMDCs To increase the immunogenicity of these GM/FL-BMDCs, genetic modification is attempted or an adjuvant is used, but unexpected side effects such as off-target effect or excessive inflammation caused by inflammatory cytokines this exists.
- the methods presented above focus only on changes in cytokines that can stimulate T cells and increase the expression of specific co-stimulatory molecules by affecting dendritic cells at the time of completion of differentiation.
- dendritic cell therapeutics aim to enhance immunogenicity in a state where differentiation is completed, but research on methods to form new dendritic cell subgroups and increase immunogenicity by controlling the intermediate stage of differentiation is almost at the laboratory level. is currently staying.
- dendritic cell therapeutics which show a significant effect in in vitro experiments, also have a problem in that they do not exhibit a tumor suppressive effect because they are inactivated due to immune checkpoint molecules increased by the tumor environment in the body. Accordingly, it is attempted to overcome the above problem by developing neutralizing antibodies against immune checkpoint molecules, but the applicable cases of tumors are limited.
- Research on the development of dendritic cell therapy for intractable cancer has been greatly developed over the past 20 years as safety has been proven as an autologous cell therapy, but the lower-than-expected anti-tumor immunity and limited therapeutic effect still remain to be resolved.
- the present invention discloses a subgroup of dendritic cells newly induced by interleukin-33 (IL-33) for the purpose of fundamentally increasing the immunogenicity of in vitro cultured dendritic cells, and by the dendritic cell subgroup By identifying that the induced anti-tumor immunity is significantly higher than that of the existing dendritic cell treatment, it was attempted to develop a more effective dendritic cell treatment method.
- IL-33 interleukin-33
- an object of the present invention is to differentiate dendritic cell progenitors into dendritic cells by culturing them in a medium containing Flt3L (FMS-like tyrosine kinase 3 ligand). It is to provide a method for producing a CD103 (cluster of differentiation 103) positive dendritic cells comprising a.
- Another object of the present invention is to provide CD103-positive dendritic cells prepared by the production method according to the present invention.
- Another object of the present invention is to provide a pharmaceutical composition for immunotherapy comprising CD103-positive dendritic cells prepared by the method according to the present invention.
- Another object of the present invention is to provide a kit for immunotherapy comprising CD103-positive dendritic cells prepared by the method according to the present invention as one component.
- Another object of the present invention is to provide a method for evaluating the immunogenicity of dendritic cells, comprising measuring the proportion of CD103-positive dendritic cells.
- dendritic cell progenitor cells are differentiated into dendritic cells by culturing them in a medium containing Flt3L (FMS-like tyrosine kinase 3 ligand), differentiation of the dendritic cells It provides a method for producing CD103 (cluster of differentiation 103) positive dendritic cells, comprising the step of treating interleukin-33 (IL-33) in the step.
- Flt3L Flt3L
- IL-33 interleukin-33
- the present inventors induced CD103-positive dendritic cells with excellent immunogenicity by treating IL-33 in the dendritic cell differentiation stage, which proved to have more effective tumor suppressive efficacy than dendritic cell therapeutics differentiated by the conventional method. was completed.
- the present inventors have demonstrated that IL-33 has a tumor suppressive effect upon direct administration to experimental animals, and developed the present invention by showing that new CD103-positive dendritic cells are induced in the spleen.
- the Flt3L may be included in the medium at a concentration of 10 to 1,000 ng/ml, but is not limited thereto.
- the culture may be made for 5 to 20 days, but is not limited thereto.
- the culture may be made for 10 days, but is not limited thereto.
- the interleukin-33 may be treated on the 3rd to 7th day from the start date of the culture, but is not limited thereto.
- the interleukin-33 may be treated at a concentration of 1 to 25 ng/ml, but is not limited thereto.
- the interleukin-33 may be treated at a concentration of 5 ng/ml on the fifth day from the culture start date, but is not limited thereto.
- the interleukin-33 may be treated at one point in the differentiation stage at which CD103-positive dendritic cells in a ratio of 30 to 100% relative to the total number of dendritic cells can be induced. not.
- the manufacturing method can induce a ratio of the number of CD103-positive type 1 myeloid-derived dendritic cells (cDC1) to 70% or more, but is not limited thereto.
- the present invention provides CD103-positive dendritic cells prepared by the production method according to the present invention.
- the present invention provides a pharmaceutical composition for immunotherapy comprising CD103-positive dendritic cells prepared by the method according to the present invention.
- the dendritic cells may induce the expression of IFN- ⁇ (Interferon gamma), but is not limited thereto.
- the dendritic cells may have increased expression of Fcgr3 (Fc receptor, IgG, low affinity III), but is not limited thereto.
- Fcgr3 Fc receptor, IgG, low affinity III
- the dendritic cells are one or more genes selected from the group consisting of CD38 (cluster of differentiation 38), CD61 (Integrin beta-3), and Tigit (T cell immunoreceptor with Ig and ITIM domains).
- CD38 cluster of differentiation 38
- CD61 Integrin beta-3
- Tigit T cell immunoreceptor with Ig and ITIM domains.
- the expression of may be increased, but is not limited thereto.
- the present invention provides (a) a first container containing a composition containing CD103-positive dendritic cells prepared by the manufacturing method according to the present invention; (b) a second container containing the tumor antigen; And (c) it provides a kit for immunotherapy comprising an instruction to mix the composition in the first container and the antigen in the second container 12 to 48 hours before administration to an individual in need thereof.
- the present invention provides a method for evaluating the immunogenicity of dendritic cells, comprising the step of measuring the ratio of CD103-positive dendritic cells.
- the method may further include, but is not limited to, evaluating the immunogenicity as good when the ratio of the number of CD103-positive dendritic cells to the total dendritic cells is 70% or more.
- the present invention provides a method for immunotherapy, comprising administering to an individual in need thereof a pharmaceutical composition comprising CD103-positive dendritic cells prepared by the method according to the present invention.
- the present invention provides the use of the composition for immunotherapy, comprising CD103-positive dendritic cells prepared by the method according to the present invention.
- the present invention provides a use of the CD103-positive dendritic cells prepared by the preparation method according to the present invention for producing an immunotherapy drug.
- the present invention revealed a subgroup of dendritic cells newly differentiated by interleuin-33 (IL-33), and as described above, dendritic cells differentiated by IL-33 are more antigen-specific cytotoxic than control dendritic cells.
- the T cell inducing ability was high, and anti-tumor immunity was strongly induced by the dendritic cell subgroup.
- IL-33 interleuin-33
- anti-tumor immunity was strongly induced by the dendritic cell subgroup.
- FIG. 1 is a schematic diagram showing the production flow of in vitro cultured dendritic cells using GM-CSF or Flt3L in time series.
- Figures 2a and 2b are a road confirming the subgroup expressing CD103, the CD103+ cDC1 subgroup change according to the treatment time of IL-33 during production of FL-33-DC (Fig. 2a) and GM-DC, GM-33-DC, It is a diagram showing the results of CD103+ dendritic cell subgroup analysis (FIG. 2b) in FL-DC and FL-33-DC, respectively.
- FIG. 3a and 3b show the results of CD103+ dendritic cell subgroup analysis in FL-DC, FL-GM-DC and FL-33-DC ( FIG. 3a ) and the analysis result of antigen-specific T cell division and activation inducibility ( FIG. 3b ). ) is a diagram showing
- Figures 4a to 4d are FL-DC, FL-GM-DC and FL-33-DC transcript analysis original data (Fig. 4a) and FL-33-DC-specific high gene expression level comparison graph (Fig. 4b), gene expression analysis confirmed by RT-PCR (Fig. 4c), and CD38, CD61, TIGIT, and Fcgr3 protein expression analysis results confirmed by flow cytometry (Fig. 4d) are shown.
- FIG. 5a and 5b show tumor growth inhibition of dendritic cell vaccine sensitized to GM-DC, GM-33-DC, FL-DC, FL-GM-DC, and FL-33-DC in the mouse EG.7 tumor model. It is a diagram showing the result of analyzing the effect (Fig. 5a) and the analysis result of cytotoxic lymphocytes induced after vaccine administration (Fig. 5b).
- FIG. 6a and 6b are the results of analyzing the tumor-derived nodule formation inhibitory effect of the dendritic cell vaccine sensitized to FL-DC, FL-GM-DC, and FL-33-DC in the mouse B16F10-OVA lung metastasis model (Fig. 6a) and the analysis results of cytotoxic lymphocytes induced after vaccine administration ( FIG. 6b ) are diagrams.
- FIG. 7a to 7d are graphs of CD103-positive dendritic cells in the spleen (Fig. 7a) after administration of GM-CSF or IL-33 to mice, tumor growth graph after administration of cytokines to the EG.7 tumor model (Fig. 7b), cytokines It is a diagram showing the ratio of CD103-positive dendritic cells in the spleen of the administered tumor model ( FIG. 7c ), and the analysis results of cytotoxic lymphocytes induced after cytokine administration ( FIG. 7d ).
- FIG. 8 is a diagram showing the results of analyzing the protein expression levels of Fcgr3 and Fcgr4 in IL-33-induced CD103-positive dendritic cells by flow cytometry.
- the present inventors in the preparation of in vitro cultured dendritic cells using a medium containing Flt3L (FMS-like tyrosine kinase 3 ligand), interleukin-33 (interleukin-33, hereinafter 'IL- 33'), the present invention was completed by discovering that CD103 (cluster of differentiation 103)-positive dendritic cells with increased immunogenicity were newly induced to significantly increase anti-tumor immunity.
- Flt3L Flt3L
- interleukin-33 interleukin-33
- FL-33-DC dendritic cells treated with IL-33 in Flt3L environment
- FL-33-DC dendritic cells treated with IL-33 in Flt3L environment
- FL-DC dendritic cells cultured in Flt3L environment
- a vaccine containing FL-33-DC when produced and administered to a tumor model, not only the FL-DC vaccine but also the conventionally used GM-DC (dendritic cultured in a GM-CSF environment) cells) and GM-33-DC (BMDC treated with IL-33 in a GM-CSF environment) it was confirmed that it can inhibit tumor growth more effectively than vaccines (see Example 5).
- GM-DC dendritic cultured in a GM-CSF environment
- GM-33-DC BMDC treated with IL-33 in a GM-CSF environment
- FL-GM-DC dendritic cells cultured under Flt3L and GM-CSF environment
- FL-GM-DC dendritic cells cultured under Flt3L and GM-CSF environment
- IL-33 treated at the differentiation stage in the preparation of in vitro cultured dendritic cell vaccine induces immunogenic CD103+ dendritic cells and induces cytotoxic T It was confirmed that the cells were more effectively induced to show a strong tumor suppressive effect (see Example 5).
- IL-33 In another embodiment of the present invention, after intraperitoneal administration of IL-33 or GM-CSF to mice, the inducing ability and tumor suppressive ability of CD103-positive dendritic cells in the spleen are analyzed, and IL-33 or It was confirmed that additional CD103-positive dendritic cells were induced in both mouse groups by GM-CSF, but it was confirmed that the anti-tumor immunity effect was strongly shown in IL-33 (see Example 7).
- the present invention relates to the differentiation of dendritic cells into dendritic cells by culturing them in a medium containing Flt3L, comprising the step of treating interleukin-33 (IL-33) in the dendritic cell differentiation stage, A method for producing dendritic cells can be provided.
- IL-33 interleukin-33
- DC dendritic cells
- APC antigen-presenting cell
- MHC major histocompatibility complex class II
- CD8+ T cell activation endogenous antigens
- DCs have a special ability to cross-present exogenous antigens through MHC class II as well as MHC class I.
- DCs can more effectively activate CD4+ and CD8+ T cells.
- the DC After acquiring the antigen, the DC, which has undergone the maturation process, moves to the lymphatic organ and presents the antigen to the naive T cells.
- T cell activation requires not only antigen presentation by APC, but also stimulation of costimulatory molecules (CD80, CD86, CD40, etc.) expressed on the surface of APC and pro-inflammatory cytokines.
- Fully mature DC induces CD4+ T cells to differentiate into Th1 (T helper 1) cells through these signals, and also activates CD8+ T cells (cytolytic T lymphocytes).
- CD4+ T cells are differentiated into Th2 cells or regulatory T cells (Tregs) in the absence of stimulation of APC co-stimulatory factors and pro-inflammatory cytokines or when stimulated by immunosuppressive cytokines.
- TAE tumor and tumor microenvironment
- the tumor and tumor microenvironment (TME) directly induces DC dysfunction or suppresses anticancer immune activity by hiding tumor antigens and secreting large amounts of immunosuppressive cytokines.
- autologous DCs are loaded with antigens and trained outside the body to express co-stimulatory factors and secrete inflammation-promoting cytokines.
- Research for inducing T cell activity is being conducted, and the preparation method of the present invention is a result of newly discovered and completed in vitro culture method for obtaining dendritic cells having excellent immunogenicity and anti-tumor efficacy in the course of such research.
- immunologicality refers to a property capable of inducing or maintaining an immune response, in particular capable of inducing an immune response, when administered to a mammal and particularly when administered to a human individual.
- the manufacturing method includes a process of culturing dendritic cell progenitor cells in a medium containing Flt3L to differentiate them into dendritic cells.
- dendritic cells when dendritic cells are cultured in the Flt3L-containing medium, dendritic cells with better immunogenicity and anti-tumor efficacy compared to the widely used GM-CSF (Granulocyte-macrophage colony-stimulating factor) are produced. It was confirmed that it was made, therefore, GM-CSF may not be contained in the dendritic cell culture medium according to the manufacturing method of the present invention.
- GM-CSF Granulocyte-macrophage colony-stimulating factor
- Flt3L is an abbreviation of FMS-like tyrosine kinase 3 ligand. It refers to a cytokine that functions as a growth factor that increases the number of cells.
- the Flt3L may be of human origin and may be a protein having the amino acid sequence of GenBank: AAA19825.1.
- the Flt3L may be included in the medium at a concentration of 10 to 1,000 ng/ml, but is not limited thereto. In one embodiment, when dendritic cells are cultured for 10 days, a medium containing 100 ng/ml of Flt3L may be used.
- the culture may be made for 5 to 20 days, preferably for 10 days, but is not limited thereto.
- the interleukin-33 may be treated on the 3rd to 7th day from the culture start date, but is not limited thereto, and treatment is preferably performed at the differentiation stage.
- the "differentiation stage” is used to refer to all successive stages in which dendritic cell progenitor cells, for example, hematopoietic bone marrow progenitor cells, are differentiated into immature dendritic cells or mature dendritic cells.
- the “immature dendritic cells” are found in the early stages of differentiation, do not express cell surface markers such as CD14, and express low levels of HLA-DR, CD86, CD80, CD83 or CD40, and CD1a like mature dendritic cells. and dendritic cells expressing CCR1, CCR2, CCR5 and CXCR1 at normal levels. Differentiation of immature dendritic cells is initiated by receiving various signals, and this differentiation leads to complete or partial differentiation depending on the combination of the signals received. Because immature dendritic cells have low levels of expressed inflammatory cytokines, they cannot activate T cells even when they come into contact with T cells.
- the “mature dendritic cell” refers to a cell formed by maturation of immature dendritic cells, and cell surface markers involved in B cell and T cell activity, for example, MHC class I or MHC class II (HLA-DR), cell adhesion Refers to a cell that expresses a factor (CD54, CD18, CD11), a co-stimulatory factor (eg, CD86, CD80, CD83 or CD40) at a high level or a relatively increased level compared to immature dendritic cells, typically mature Dendritic cells express high levels of CCR7 and CXCR4.
- a factor CD54, CD18, CD11
- a co-stimulatory factor eg, CD86, CD80, CD83 or CD40
- Mature dendritic cells release proinflammatory cytokines, and increase proliferation of primitive allogeneic T cells and syngeneic T cells in a mixed lymphocyte reaction and / or other immune response-related cytokines are characterized by increased expression and secretion.
- the production method of the present invention is not limited to the specified time and concentration, and the treatment time and concentration of interleukin-33 may be appropriately adjusted by those skilled in the art depending on the state of dendritic cell progenitor cells, the number of cells, the culture environment, etc. . Therefore, the interleukin-33 may be treated at an appropriate concentration, for example, may be treated at a concentration of 1 to 25 ng/ml, but is not limited thereto.
- the treatment time and concentration of the interleukin-33 may be treated at a time point at which the ratio of the number of CD103 positive dendritic cells to the total dendritic cells can be induced to 30 to 100%.
- a time point at which the ratio of the number of CD103 positive dendritic cells to the total dendritic cells can be induced to 30 to 100%.
- interleukin-33 can be treated by selecting any one of the above periods, preferably CD103 Interleukin-33 can be treated by selecting a time point when the ratio of positive dendritic cells is highest.
- the manufacturing method may induce a ratio of the number of CD103-positive type 1 myeloid-derived dendritic cells (cDC1) to 70% or more, but is not limited thereto.
- the present invention can provide CD103-positive dendritic cells prepared by the production method according to the present invention.
- the present invention can provide a pharmaceutical composition for immunotherapy comprising CD103-positive dendritic cells prepared by the method according to the present invention.
- the dendritic cells can induce the expression of IFN- ⁇ (Interferon gamm), but is not limited thereto.
- the dendritic cells may have increased expression of Fcgr3 (Fc receptor, IgG, low affinity III), but is not limited thereto.
- Fcgr3 Fc receptor, IgG, low affinity III
- the dendritic cells have increased expression of one or more genes selected from the group consisting of CD38 (cluster of differentiation 38), CD61 (Integrin beta-3), and Tigit (T cell immunoreceptor with Ig and ITIM domains). may be, but is not limited thereto.
- the Fcgr3 plays an important role in host defense such as phagocytosis of pathogens and regulation of immune cell differentiation.
- the CD38 is a glycoprotein on the surface of immune cells such as natural killer cells, and the CD61 is a differentiation cluster expressed in platelets and white blood cells.
- the TIGIT is an immune receptor present in T cells or natural killer cells. The increase in their gene expression means that the immune effect is excellent.
- the present invention provides an immunotherapy method comprising administering to an individual in need thereof a pharmaceutical composition comprising CD103-positive dendritic cells prepared by the method according to the present invention.
- the present invention can provide the use of a composition comprising CD103-positive dendritic cells prepared by the manufacturing method according to the present invention for immunotherapy.
- the present invention may provide the use of CD103-positive dendritic cells prepared by the production method according to the present invention for producing an immunotherapy drug.
- a method for immunotherapy comprising administering the interleukin-33 to an individual, but is not limited thereto.
- the interleukin-33 may newly form CD103-positive dendritic cells in vivo, but is not limited thereto.
- the in vivo injection of the interleukin-33 may be performed at an appropriate dose, and may be administered at 5 to 500 ⁇ g/kg, but is not limited thereto.
- the in vivo administration of the interleukin-33 may be performed daily for 4 to 11 days, but is not limited thereto.
- the interleukin-33 can increase the expression of the Fcgr3 (Fc receptor, IgG, low affinity III) or Fcgr4 (Fc receptor, IgG, low affinity IV) gene of newly formed CD103-positive dendritic cells in vivo.
- Fcgr3 Fc receptor, IgG, low affinity III
- Fcgr4 Fc receptor, IgG, low affinity IV
- Fcgr3 Fc receptor, IgG, low affinity III
- CD103-positive dendritic cells induced in vitro and in vivo after the interleukin-33 treatment, but is limited thereto. it is not
- the term “pharmaceutical composition for immunotherapy” may be used interchangeably with the term “cell therapy agent”, and in order to restore the function of cells and tissues, live autologous, allogeneic or A drug used for the purpose of treatment, diagnosis and prevention through a series of actions such as proliferation and selection of xenogenic cells in vitro or changing the biological characteristics of cells by other methods.
- Cell therapy products have been administered as pharmaceuticals since 1993 in the United States and 2002 in Korea. These cell therapy products can be broadly classified into two fields. The first is “stem cell therapy” for tissue regeneration or organ function recovery, and the second is immune response regulation such as suppression of immune response or enhancement of immune response in vivo. It is an “immune cell therapy” for
- the pharmaceutical composition according to the present invention may further include suitable carriers, excipients and diluents commonly used in the preparation of pharmaceutical compositions.
- the excipient may be, for example, at least one selected from the group consisting of a diluent, a binder, a disintegrant, a lubricant, an adsorbent, a humectant, a film-coating material, and a controlled-release additive.
- the pharmaceutical composition according to the present invention can be prepared according to a conventional method, respectively, in powders, granules, sustained-release granules, enteric granules, liquids, eye drops, elsilic, emulsions, suspensions, alcohols, troches, fragrances, and limonaade.
- Carriers, excipients and diluents that may be included in the pharmaceutical composition according to the present invention include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
- the injection according to the present invention includes distilled water for injection, 0.9% sodium chloride injection, Ringel injection, dextrose injection, dextrose + sodium chloride injection, PEG (PEG), lactated Ringel injection, ethanol, propylene glycol, non-volatile oil-sesame oil , solvents such as cottonseed oil, peanut oil, soybean oil, corn oil, ethyl oleate, isopropyl myristate, and benzene benzoate; Solubilizing aids such as sodium benzoate, sodium salicylate, sodium acetate, urea, urethane, monoethyl acetamide, butazolidine, propylene glycol, tweens, nijeongtinamide, hexamine, and dimethyl acetamide; Weak acids and their salts (acetic acid and sodium acetate), weak bases and their salts (ammonia and ammonium acetate), organic compounds, proteins, buffers such as albumin, pe
- composition according to the present invention is administered in a pharmaceutically effective amount.
- pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is determined by the type, severity, drug activity, and type of the patient's disease; Sensitivity to the drug, administration time, administration route and excretion rate, treatment period, factors including concurrent drugs and other factors well known in the medical field may be determined.
- the pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or may be administered in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or multiple times. In consideration of all of the above factors, it is important to administer an amount capable of obtaining the maximum effect with a minimum amount without side effects, which can be easily determined by a person skilled in the art to which the present invention pertains.
- the pharmaceutical composition of the present invention may be administered to an individual by various routes.
- Any mode of administration may be contemplated, for example, subcutaneous injection, intraperitoneal administration, intravenous injection, intramuscular injection, paraspinal space (intrathecal) injection, sublingual administration, buccal administration, rectal insertion, vaginal insertion, It can be administered according to ocular administration, ear administration, nasal administration, skin administration, transdermal administration, etc., and preferably intradermally, intranodally, subcutaneously, intravenously, or directly intratumorally. There is this. However, the optimal route of administration has not yet been established.
- the pharmaceutical composition of the present invention is determined according to the type of drug as an active ingredient along with several related factors such as the disease to be treated, the route of administration, the patient's age, sex, weight, and the severity of the disease.
- “individual” means a subject in need of treatment for a disease, and more specifically, human or non-human primates, mice, rats, dogs, cats, horses, and cattle means mammals such as
- administration means providing a predetermined composition of the present invention to an individual by any suitable method.
- prevention means any action that suppresses or delays the onset of a target disease
- treatment means that the target disease and its metabolic abnormalities are improved or It means any action that is changed for the better.
- the present invention provides (a) a first container containing a composition comprising CD103-positive dendritic cells prepared by the manufacturing method according to the present invention; (b) a second container containing the tumor antigen; And (c) it can provide a kit for immunotherapy comprising an instruction to mix the composition in the first container and the antigen in the second container 12 to 48 hours before administration to an individual in need thereof.
- TAAs tumor-associated antigens
- Tumor-specific antigens induce a tumor-specific immune response in the host, but in the case of tumor-associated antigens expressed not only in tumor cells but also in normal cells, self-tolerance expression may not induce a tumor-specific immune response in the host. .
- Mixing the composition in the first container and the antigen in the second container is a process of loading the antigen on the dendritic cells.
- a method of loading antigens on dendritic cells in general, a method of killing and culturing peptides, proteins, and autologous/allogeneic cancer cells is used. Short synthetic peptides (8-15 aa) are mounted directly on MHC molecules on the surface of dendritic cells, whereas long synthetic peptides (28-35 aa), proteins and cancer cells undergo peptide processing prior to loading on MHC molecules.
- a CD8+ T cell epitope for TAA is being used in clinical trials, and the patient's HLA haplotype must be known and capable of binding to a specific haplotype.
- a long synthetic peptide it can be cross-presented during antigen processing in dendritic cells, so that it can induce not only CD8+ T cells but also CD4+ T cell responses and present antigens for a longer period of time.
- the present invention provides a method for evaluating the immunogenicity of dendritic cells, comprising the step of measuring the ratio of CD103-positive dendritic cells.
- the method may further include, but is not limited to, evaluating the immunogenicity as good when the ratio of the number of CD103-positive dendritic cells to the total dendritic cells is 70% or more.
- the CD103-positive dendritic cells are a marker of cDC1 (type 1 conventional DC), and in one embodiment of the present invention, it was confirmed that the higher the ratio of the CD103+ dendritic cell subgroup, the stronger the antigen-specific T cells are induced.
- the bone marrow cells were isolated from the hind legs of mice, they were cultured in a GM-CSF environment at a concentration of 20 ng/ml.
- GM-DC dendritic cells cultured for 7 days from the first day by exchanging with a new culture medium
- GM-33-DC dendritic cells treated with 5 ng/ml of IL-33 on the third day of the GM-DC culture
- dendritic cells prepared by culturing bone marrow cells in an Flt3L environment at a concentration of 100 ng/ml for 10 days they were named FL-DC.
- dendritic cells cultured by adding 5 ng/ml of IL-33 on the 3rd to 7th day of the FL-DC culture were named FL-33-DC.
- Cell analysis was performed for GM-DC and GM-33-DC on the 7th day of culture, and for FL-DC and FL-33-DC on the 10th day of culture.
- Dendritic cells for vaccine administration for confirmation of anticancer effect were treated with egg white albumin (Ovalbumin, hereinafter 'OVA') corresponding to the antigen one day before use, and then administered to tumor model mice (see schematic diagram in FIG. 1 ).
- Ovalbumin hereinafter 'OVA'
- CD103+ cDC1 with strong antitumor immunogenicity in GM-DC, GM-33-DC, FL-DC, and FL-33-DC prepared in Example 1 was analyzed.
- CD103+ cDC1 was hardly induced in GM-DC, and the CD103+ cDC1 subgroup was not induced significantly in GM-33-DC to which IL-33 was added.
- FL-DC XCR1 was expressed but CD103 was hardly expressed.
- FL-33-DC CD103+ cDC1 accounted for more than 75% of total dendritic cells ( FIG. 2b ).
- Example 2 it was confirmed that CD103+ dendritic cells were newly induced in FL-33-DC. Accordingly, the present inventors compared with FL-33-DC whether or not CD103+ cDC1 was induced when GM-CSF was added during the production process of FL-DC, which is a conventional method.
- FL-DC, FL-GM-DC and FL-33-DC were treated with OVA protein and the OVA antigen-specific T cell receptor was After co-culture with OT-I mouse T cells, the proliferation of OT-1 T cells and the expression of IFN- ⁇ , one of the activating cytokines, were investigated.
- FL-33-DC and FL-GM-DC showed higher proliferative capacity of OT-1 T cells than FL-DC.
- FL-33-DC effectively induced IFN- ⁇
- FL-GM-DC did not induce IFN- ⁇ ( FIG. 3b ).
- the present inventors conducted transcriptomic analysis of FL-DC, FL-GM-DC and FL-33-DC.
- each dendritic cell showed a specific gene expression pattern (Fig. 4a). Among them, it was found that the expression levels of CD38, CD61, Tigit, and Fcgr3 were specifically high in FL-33-DC (Fig. 4b), and as a result of performing RT-PCR after actually isolating RNA, the genes were found to be FL It was confirmed that -33-DC was specifically highly expressed (FIG. 4c).
- the four genes were analyzed at the protein level by flow cytometry.
- Example 3 it was confirmed that FL-33-DC had significantly higher antigen-specific T cell induction and activation ability than FL-DC and FL-GM-DC, and in Example 4, FL-33-DC was an immunogen It was confirmed that the expression of sex-related CD38, CD61 and Fcgr3 was relatively high. Therefore, in order to check whether it can be applied to the treatment of tumors, the dendritic cell vaccine prepared by the method shown in the schematic diagram of FIG. 1 was injected subcutaneously into EG.7 tumor-inoculated mice, on the 3rd and 10th days after tumor inoculation, respectively. Then, tumor growth was monitored.
- Example 5 the anti-tumor immunity was most strongly induced in mice administered with the FL-33-DC vaccine, and it was confirmed whether the application was possible in a lung metastasis model.
- the dendritic cell vaccine prepared by the method shown in the schematic diagram of FIG. 1 was subcutaneously injected into the B16F10-OVA lung metastasis model on the 3rd and 10th days after tumor inoculation, respectively, and then on the 16th day, nodular formation in the lungs was analyzed. .
- Example 7 Tumor suppression and induction of CD103-positive dendritic cells in vivo through IL-33 administration
- the present inventors analyzed the inducibility and tumor suppression ability of CD103-positive dendritic cells in the spleen.
- Example 7 both IL-33 and GM-CSF could induce CD103-positive dendritic cells, but the anti-tumor immune response was completely different. Therefore, an attempt was made to identify a marker that can divide the difference between the two.
- FL-33-DC of the present invention unlike FL-DC or FL-GM-DC, highly expresses CD38, CD61, and Fcgr3, and increases immunogenicity CD103+ cDC1, and CD103+ expressing these molecules
- cDC1 exhibits an improved cancer treatment effect by effectively inducing antigen-specific cytotoxic T lymphocytes, it is expected to be widely used as a cell therapy for immunotherapy.
- Fcgr3 is commonly expressed in CD103+ cDC1 among dendritic cells produced in vitro and in vivo by IL-33, it is thought that if the expression of this molecule can be enhanced, it can be used for tumor treatment.
- the present invention revealed a subgroup of dendritic cells newly differentiated by interleuin-33 (IL-33).
- IL-33 interleuin-33
- dendritic cells differentiated by IL-33 are more antigen-specific cytotoxic than control dendritic cells.
- the T cell induction ability was high, and anti-tumor immunity was strongly induced by the dendritic cell subgroup.
- the production method of the present invention and the in vitro cultured dendritic cells using the same can provide a new immune cell therapy that can dramatically increase the therapeutic effect, and thus have industrial applicability.
Abstract
Description
Claims (23)
- 수지상세포 전구세포를 Flt3L (FMS-like tyrosine kinase 3 ligand)이 포함된 배지에서 배양하여 수지상세포로 분화시킴에 있어서, 상기 수지상세포의 분화 단계에서 인터류킨-33 (Interleukin-33, IL-33)을 처리하는 단계를 포함하는, CD103 (cluster of differentiation 103) 양성 수지상세포의 제조방법.
- 제1항에 있어서,상기 Flt3L은 배지에 10 내지 1,000 ng/ml의 농도로 포함되는 것을 특징으로 하는, CD103 양성 수지상세포의 제조방법.
- 제1항에 있어서,상기 배양은 5 내지 20일 동안 이루어지는 것을 특징으로 하는, CD103 양성 수지상세포의 제조방법.
- 제3항에 있어서,상기 배양은 10일 동안 이루어지는 것을 특징으로 하는, CD103 양성 수지상세포의 제조방법.
- 제1항에 있어서,상기 인터류킨-33은 배양 개시일로부터 3 내지 7일째 되는 날 처리하는 것을 특징으로 하는, CD103 양성 수지상세포의 제조방법.
- 제1항에 있어서,상기 인터류킨-33은 1 내지 25 ng/ml의 농도로 처리하는 것을 특징으로 하는, CD103 양성 수지상세포의 제조방법.
- 제1항에 있어서,상기 인터류킨-33은 배양 개시일로부터 5일째 되는 날 5 ng/ml의 농도로 처리하는 것을 특징으로 하는, CD103 양성 수지상세포의 제조방법.
- 제1항에 있어서,상기 인터류킨-33은 전체 수지상세포 대비 30 내지 100% 수 비율의 CD103 양성 수지상세포가 유도될 수 있는 분화 단계의 일 시점에서 처리되는 것을 특징으로 하는, CD103 양성 수지상세포의 제조방법.
- 제1항에 있어서,상기 제조방법은 전체 수지상세포 대비 CD103 양성 제1형 골수성유래 수지상세포 (cDC1) 수 비율을 70% 이상으로 유도하는 것을 특징으로 하는, CD103 양성 수지상세포의 제조방법.
- 제1항에 있어서,상기 수지상세포는 IFN-γ(Interferon gamm)의 발현을 유도하는 것을 특징으로 하는, CD103 양성 수지상세포의 제조방법.
- 제1항에 있어서,상기 수지상세포는 Fcgr3 (Fc receptor, IgG, low affinity III)의 발현이 증가된 것을 특징으로 하는, CD103 양성 수지상세포의 제조방법.
- 제1항에 있어서,상기 수지상세포는 CD38 (cluster of differentiation 38), CD61 (Integrin beta-3), 및 Tigit (T cell immunoreceptor with Ig and ITIM domains)로 이루어지는 군으로부터 선택된 하나 이상의 유전자의 발현이 증가된 것을 특징으로 하는, CD103 양성 수지상세포의 제조방법.
- 제1항 내지 제12항 중 어느 한 항의 제조방법으로 제조된, CD103 양성 수지상세포.
- 제1항 내지 제12항 중 어느 한 항의 제조방법으로 제조된 CD103 양성 수지상세포를 포함하는, 면역항암치료용 약학적 조성물.
- 제14항에 있어서,상기 수지상세포는 IFN-γ(Interferon gamm)의 발현을 유도하는 것을 특징으로 하는, 면역항암치료용 약학적 조성물.
- 제14항에 있어서,상기 수지상세포는 Fcgr3 (Fc receptor, IgG, low affinity III)의 발현이 증가된 것을 특징으로 하는, 면역항암치료용 약학적 조성물.
- 제14항에 있어서,상기 수지상세포는 CD38 (cluster of differentiation 38), CD61 (Integrin beta-3), 및 Tigit (T cell immunoreceptor with Ig and ITIM domains)로 이루어지는 군으로부터 선택된 하나 이상의 유전자의 발현이 증가된 것을 특징으로 하는, 면역항암치료용 약학적 조성물.
- 하기 (a) 내지 (c)를 포함하는 면역항암치료용 키트:(a)제1항 내지 제12항 중 어느 한 항의 제조방법으로 제조된 CD103 양성 수지상세포를 포함하는 조성물이 수용된 제1용기;(b)종양 항원이 수용된 제2용기; 및(c)상기 제1용기의 조성물 및 제2용기의 항원을 이를 필요로하는 개체에 투여하기 12 내지 48시간 전에 혼합할 것이 기재된 지시서.
- CD103 양성 수지상세포의 비율을 측정하는 단계를 포함하는, 수지상세포의 면역원성 평가 방법.
- 제19항에 있어서,상기 방법은 전체 수지상세포 대비 CD103 양성 수지상세포의 수 비율이 70% 이상인 경우 면역원성이 좋은 것으로 평가하는 단계를 더 포함하는 것을 특징으로 하는, 수지상세포의 면역원성 평가 방법.
- CD103 양성 수지상세포를 포함하는 약학적 조성물을 이를 필요로 하는 개체에 투여하는 단계를 포함하는 면역항암치료 방법으로, 상기 CD103 양성 수지상세포는 제1항 내지 제12항 중 어느 한 항의 제조방법으로 제조된 것을 특징으로 하는, 면역항암치료 방법.
- CD103 양성 수지상세포를 포함하는 조성물의 면역항암치료 용도로, 상기 CD103 양성 수지상세포는 제1항 내지 제12항 중 어느 한 항의 제조방법으로 제조된 것을 특징으로 하는, 면역항암치료 용도.
- 면역항암치료 약제를 생산하기 위한 CD103 양성 수지상세포의 용도로, 상기 CD103 양성 수지상세포는 제1항 내지 제12항 중 어느 한 항의 제조방법으로 제조된 것을 특징으로 하는, CD103 양성 수지상세포의 용도.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180076981.6A CN116490196A (zh) | 2020-11-17 | 2021-11-16 | 通过处理白细胞介素-33制备免疫原性提高的分化簇103+fcgr3+树突状细胞的方法以及包含上述树突状细胞的用于免疫抗癌治疗的药物组合物 |
US18/037,293 US20240002798A1 (en) | 2020-11-17 | 2021-11-16 | Method for preparing immunogenicity-enhanced cd103+ fcgr3+ dendritic cell by treatment with interleukin-33 and pharmaceutical composition comprising same dendritic cell for cancer immunotherapy |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200153308 | 2020-11-17 | ||
KR10-2020-0153308 | 2020-11-17 | ||
KR10-2021-0158012 | 2021-11-16 | ||
KR1020210158012A KR20220067519A (ko) | 2020-11-17 | 2021-11-16 | 인터류킨-33을 처리하여 면역원성이 향상된 CD103+ Fcgr3+ 수지상세포의 제조방법 및 상기 수지상세포를 포함하는 면역항암치료용 약학적 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022108306A1 true WO2022108306A1 (ko) | 2022-05-27 |
Family
ID=81709392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/016813 WO2022108306A1 (ko) | 2020-11-17 | 2021-11-16 | 인터류킨-33을 처리하여 면역원성이 향상된 cd103+ fcgr3+ 수지상세포의 제조방법 및 상기 수지상세포를 포함하는 면역항암치료용 약학적 조성물 |
Country Status (2)
Country | Link |
---|---|
US (1) | US20240002798A1 (ko) |
WO (1) | WO2022108306A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111012905A (zh) * | 2013-10-07 | 2020-04-17 | 宾夕法尼亚大学理事会 | 具有作为佐剂的白介素-33的疫苗 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040115224A1 (en) * | 2002-12-16 | 2004-06-17 | Tsuneya Ohno | Preparation and administration of hybrid cell vaccines for the prevention of cancer |
WO2014121840A1 (en) * | 2013-02-07 | 2014-08-14 | Medizinische Hochschule Hannover | Induced dendritic cells and uses thereof |
-
2021
- 2021-11-16 US US18/037,293 patent/US20240002798A1/en active Pending
- 2021-11-16 WO PCT/KR2021/016813 patent/WO2022108306A1/ko active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040115224A1 (en) * | 2002-12-16 | 2004-06-17 | Tsuneya Ohno | Preparation and administration of hybrid cell vaccines for the prevention of cancer |
WO2014121840A1 (en) * | 2013-02-07 | 2014-08-14 | Medizinische Hochschule Hannover | Induced dendritic cells and uses thereof |
Non-Patent Citations (3)
Title |
---|
CHEN LUJUN, SUN RUNZI, XU JUNCHI, ZHAI WENSI, ZHANG DACHUAN, YANG MIN, YUE CUIHUA, CHEN YICHAO, LI SONG, TURNQUIST HETH, JIANG JIN: "Tumor-Derived IL33 Promotes Tissue-Resident CD8+ T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy", CANCER IMMUNOLOGY RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 8, no. 11, 2 November 2020 (2020-11-02), US , pages 1381 - 1392, XP055932859, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-19-1024 * |
DONYE DOMINGUEZ, YE CONG, GENG ZHE, CHEN SIQI, FAN JIE, QIN LEI, LONG ALAN, WANG LONG, ZHANG ZHUOLI, ZHANG YI, FANG DEYU, KUZEL TI: "Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO., US, vol. 198, no. 3, 23 December 2016 (2016-12-23), US , pages 1365 - 1375, XP055551251, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1501399 * |
NG SEE LIANG, TEO YI JUAN, SETIAGANI YOLANDA APHRILIA, KARJALAINEN KLAUS, RUEDL CHRISTIANE: "Type 1 Conventional CD103+ Dendritic Cells Control Effector CD8+ T Cell Migration, Survival, and Memory Responses During Influenza Infection", FRONTIERS IN IMMUNOLOGY, FRONTIERS MEDIA, LAUSANNE, CH, vol. 9, 21 December 2018 (2018-12-21), Lausanne, CH , pages 1 - 15, XP055932857, ISSN: 1664-3224, DOI: 10.3389/fimmu.2018.03043 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111012905A (zh) * | 2013-10-07 | 2020-04-17 | 宾夕法尼亚大学理事会 | 具有作为佐剂的白介素-33的疫苗 |
CN111012905B (zh) * | 2013-10-07 | 2023-12-22 | 宾夕法尼亚大学理事会 | 具有作为佐剂的白介素-33的疫苗 |
Also Published As
Publication number | Publication date |
---|---|
US20240002798A1 (en) | 2024-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014157918A1 (ko) | 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물 | |
Marrack et al. | The development of helper T cell precursors in mouse thymus. | |
Wolfram et al. | Antigen presentation by Leishmania mexicana‐infected macrophages: activation of helper T cells specific for amastigote cysteine proteinases requires intracellular killing of the parasites | |
WO2022108306A1 (ko) | 인터류킨-33을 처리하여 면역원성이 향상된 cd103+ fcgr3+ 수지상세포의 제조방법 및 상기 수지상세포를 포함하는 면역항암치료용 약학적 조성물 | |
WO2015026215A9 (ko) | 바이구아나이드 유도체 화합물을 유효성분으로 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약제학적 조성물 | |
WO2020197216A1 (ko) | Nk세포배양배지용 첨가조성물, 상기 첨가조성물을 이용한 nk세포배양방법 및 상기 배양방법으로 얻어진 피부트러블개선용 화장료조성물 | |
WO2015167243A1 (ko) | 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도 | |
EP0630257B1 (en) | Thymus-derived, immune-enhancing agent for therapeutic use in immunocompromised hosts | |
WO2015199402A1 (ko) | 특정 유전자 발현이 증가된 수지상세포의 제조방법 및 이를 이용하여 제조된 수지상세포를 포함하는 자가면역질환 치료 또는 예방용 조성물 | |
AU2020234373B9 (en) | Novel peptide and use thereof | |
WO2017069512A1 (ko) | 바이러스 항원 특이적인 t 세포의 유도 및 증식 방법 | |
WO2016027990A1 (ko) | Dusp5를 유효성분으로 모두 포함하는 골대사성 질환의 예방 또는 치료용 약학적 조성물 | |
WO2015023147A1 (ko) | mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽 줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 | |
Dennert et al. | Induction and properties of cytotoxic T cells specific for hapten-coupled tumor cells | |
WO2018034523A1 (ko) | Jak 억제제를 포함하는 면역반응 억제용 조성물 | |
WO2021177599A1 (en) | METHOD FOR PRODUCING MEMORY-LIKE NK CELLS WITH ABILITY TO EXPRESS HIGHER LEVELS OF NCRS, CYTOTOXICITY, AND IFN-γ THAN NK CELLS IN HUMAN PERIPHERAL BLOOD | |
WO2021149971A1 (ko) | 신규 화합물 및 이의 용도 | |
KR20220067519A (ko) | 인터류킨-33을 처리하여 면역원성이 향상된 CD103+ Fcgr3+ 수지상세포의 제조방법 및 상기 수지상세포를 포함하는 면역항암치료용 약학적 조성물 | |
WO2020071652A1 (ko) | 세포의 텔로미어를 신장시키는 방법 | |
WO2018143652A1 (ko) | 면역 관용성 플라즈마사이토이드 수지상 세포 및 그 제조방법 | |
KR20130106786A (ko) | 골수유래억제세포 및 레바미피드를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
WO2019212123A1 (ko) | 수지상세포의 이동능을 증가시키는 방법 및 이의 용도 | |
WO2015194710A1 (ko) | Stat3 억제제가 처리된 간엽줄기세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
WO2018143649A1 (ko) | 자가 면역 질환의 예방 또는 치료용 약학적 조성물 및 그 제조방법 | |
WO2018143650A1 (ko) | 과민성 면역 질환의 예방 또는 치료용 약학적 조성물 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21895074 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18037293 Country of ref document: US Ref document number: 202180076981.6 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21895074 Country of ref document: EP Kind code of ref document: A1 |